Last reviewed · How we verify
Kleb4V target dose
At a glance
| Generic name | Kleb4V target dose |
|---|---|
| Sponsor | LimmaTech Biologics AG |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kleb4V target dose CI brief — competitive landscape report
- Kleb4V target dose updates RSS · CI watch RSS
- LimmaTech Biologics AG portfolio CI